Low levels of serum placental growth factor (PlGF) in pregnancy are associated with preeclampsia
Lecarpentier et al. (Obstetrics & Gynecology, 2019) sought to determine whether urinary levels of PlGF during pregnancy are associated with adverse outcomes composite adverse outcomes <34 weeks of gestation
Ancillary study of the randomized Heparin-Preeclampsia trial
Pregnant women with early-onset (<34 weeks) preeclampsia
In the parent study
All women were treated with aspirin
Randomized to and then randomized to receive either low-molecular-weight heparin (LMWH) or aspirin
In this substudy
Urinary levels of PlGF and urinary creatinine were measured at 10w0d to 13w6d | 14w0d to 17w6d | 18w0d to 21w6d | 22w0d to 25w6d | 26w0d to 29w6d | 30w0d to 33w6d | 34w0d to 37w6d
Composite of adverse pregnancy outcomes: Preeclampsia | FGR | Placental abruption | Perinatal death | Maternal death
For the prediction analysis
Mid-pregnancy samples were used (22 to 26 weeks) from those women who went on to develop either (1) composite adverse outcomes or preeclampsia <34 weeks and compared to those who did not develop these adverse events
Urine samples were taken from 187 patients
LMWH plus aspirin (n=93) | Aspirin alone (n=94)
There was not difference between the groups for the following
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan